Two trade names of deferasirox (Osveral® and Exjade®) in reduction of iron overload parameters in major beta-thalassemia patients: A randomized open labeled clinical trial

Autor: Mohammadreza Rafati, Hossein Karami, Bita Lashtoo-Aghaee, Bahareh Lashtoo-Aghaee, Mojdeh Dabirian, Razieh Avan

Publikováno v: Caspian Journal of Internal Medicine, Vol 13, Iss 1, Pp 61-69 (2022)

Background: Beta-thalassemia major patients typically require chronic transfusion and iron-chelating agents to reduce serum iron overload. Osveral® is an available Iranian brand name of deferasirox used by majority of thalassemic patients. The aim o

Externí odkaz: https://doaj.org/article/23b091471b5d41bfb74bfc4191fcc45a

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Efficacy and safety of Iranian made Deferasirox (Osveral®)in Iranian major thalassemic patients with transfusional iron overload: A one year prospective multicentric open-label non-comparative study

Autor: Eshghi, P., Farahmandinia, Z., Mohammad Ali Molavi, Naderi, M., Jafroodi, M., Hoorfar, H., Davari, K., Azarkeivan, A., Keikhaie, B., Ansari, S., Arasteh, M.

Publikováno v: Scopus-Elsevier
DARU : Journal of Faculty of Pharmacy, Tehran University of Medical Sciences

Purpose of the study to determine the efficacy, adverse effects and safety of a new Iranian generic product of deferasirox (Osveral®) in Iranian transfusion dependent major thalassemic (TD-MT) patients. Methods In 9 main thalassemia treatment center

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::4bb59a68735f0a597a2ea3a8f4dac7ad
http://www.scopus.com/inward/record.url?eid=2-s2.0-80053455572&partnerID=MN8TOARS

Efficacy and safety of Iranian made Deferasirox (Osveral®) in Iranian major thalassemic patients with transfusional iron overload: A one year prospective multicentric open-label non-comparative study.

Autor: Eshghi P; Department of Pediatric Hematology and Oncology, Mofid Children Hospital, Shahid Beheshti University of Medical Science, Tehran., Farahmandinia Z, Molavi M, Naderi M, Jafroodi M, Hoorfar H, Davari K, Azarkeivan A, Keikhaie B, Ansari S, Arasteh M

Publikováno v: Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences [Daru] 2011; Vol. 19 (3), pp. 240-8.